Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC).

In 30 seconds

This phase I/II clinical trial evaluated the safety and efficacy of pembrolizumab combined with gemcitabine in 16 patients with previously-treated advanced non-small cell lung cancer (NSCLC). The study found that a novel tumor inflammation score, based on regulatory T cell and T cell density, correlated with disease response (p < 0.002), suggesting its potential as a predictive biomarker.

Key findings

• Elevated frequencies of regulatory T cells near CD3 T cells at baseline were associated with improved treatment outcomes (p < 0.05).
• The novel tumor inflammation score correlated with disease response (p < 0.002).
• High autoantibody responses trended toward worse outcomes (p = 0.06).

Why it matters

Understanding the tumor microenvironment and immune cell interactions can enhance predictive capabilities for treatment responses in NSCLC, potentially guiding therapeutic decisions and patient management.